google this for the link to ihub post:
'Excerpts from Court Filing in CSM Case'
did something similar happen to endcoyte? we may never know.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
If the growth prospects are so good why did the stock just drop from 1.30 to .40 in 3 months? Sounds fishy to me.
Second: This is the ECYT board not the pump and dump board.
They have ECYT as a "Strong buy" today - hmmmmmmm
"After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ECYT, as the firm currently has a positive Zacks Earnings ESP, so another beat could be around the corner.
This is particularly true when you consider that ECYT has a great Zacks Rank #1 (Strong Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ECYT could see another beat at its next report, especially if recent trends are any guide."
Even though the PT is the same, I guess they actually dropped coverage for a few months.
From FLY on the Wall:
July 8, 2014
05:30 EDT ECYT Endocyte assumed with a Buy at Brean Capital
22 PT is well calculated and should occur in two months. It is certainly true that OS for NSCLC is around 13 to 14 months compared to 9 months. New partnership should be in works, they withdraw triple Negative breast cancer. They dont want to spend single dime without partner. I believe they are negotiating new partners for sure.
Assuming they lose. Which they will based on the information known. They most certainly were in breach and misleading. Hopefully they will not drag it out and just settle. Question is how much?? I am guessing (and think they deserve) to lose $250 million. What the hell do they need it for anyways?? There products are complete #$%$. Might as well spend all cash by reimbursing ripped-off investors. They may need to do another secondary at 3-4 a share to pay for the damage they did.
What kind of partner wants a rejected project? What kind of partner wants to pick up after Merck rejects? What kind of partner wants a company that will owe shareholders more cash than it has at hand?
Must not be going real good for the Law Firms, most are putting out their 2nd Press Release on the 1 lawsuit filed. Just like the Sokolove ads for Mesothelioma that have been running for the last 10 years on TV near me. Just trolling for people so they can get their 33% commission plus expenses while the investors might be luck to see a couple of cents per share. Love the US Tort system do ya?
These lawsuits rarely recover anything significant. It has to be proven that Endocyte knew the trial would be halted before the offering. Any shareholder who bought at $21 is probably still holding some stock in hopes of the pipeline so they are shooting themselves if they sign up to give away 30% of their money to a lawyer.
Merck Rejection entirely based on different reason.
1. Ofcourse Ovarian failure - No immediate money to make. But, commitments for TNBC, NSCLC trials.
2. Their own product for NSCLC. Anti-PD-1. That is first line of treatment
What is different about NSCLC vs Ovarian
1. Docetaxel is different drug then Doxil.
2. Ovarian cancer is different from NSCLC
Vintafolide is all about targeted therapy, it is entirely possible that Doxil is already working better with or without targeted approach, therefore failure. But, same may not be true for Docetaxel. Docetaxel may be more potent with targeted approach hence significant PFS improvement and OS. If they have achieved PFS hurdle for Phase-II NSCLC, they will certainly achieve OS end point.
Merck also spent $3.85B (or agreed to) on IDIX 9 days before opting out of ECYT partnership. They paid too much for the "potential" of IDIX's Hepatitis C pipeline. It just made sense that they would decide to move on. Had Endocyte not done a secondary for $21 to raise over $100M in cash, what would the PPS be today?
It is a strong buy at $6.47.Buy and hold stock.You will be rewarded.
Sentiment: Strong Buy
Just sour apples is all.Those who bought att $21 are unhappy.Those who bought at $6 are ecstatic.It is the law of the jungle.It happened to me with FOLD last year.Now it has recovered.Learn to live with it.
Sentiment: Strong Buy